B형 간염 치료제 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of hepatitis B therapeutics Market

The global hepatitis B therapeutics market is witnessing substantial growth due to the rising prevalence of hepatitis B virus (HBV) infections and increased adoption of antiviral treatments. The market was valued at USD 2.33 billion in 2024, projected to reach USD 2.48 billion in 2025, and expected to grow significantly to USD 6.25 billion by 2032, reflecting a strong upward trend. North America dominated the market in 2024, accounting for 53.65% of the global share, owing to advanced healthcare infrastructure, high treatment adoption, and robust R&D investments in HBV therapies.

Market Drivers

The primary driver of market growth is the increasing global prevalence of hepatitis B, a severe liver infection caused by HBV. Transmission occurs via blood, body fluids, sexual contact, and from mother to child during birth. According to the World Health Organization (WHO, April 2024), approximately 254 million people worldwide-around 3.3% of the global population-were infected with hepatitis B in 2022, while only 2.6% of chronic HBV patients received treatment. This high patient population necessitates effective therapeutics, driving demand in both developed and emerging markets.

Government initiatives, such as China's "Supporting China's Action to Eliminate the Public Health Threat of Viral Hepatitis by 2030" program launched in January 2025, are further increasing awareness, improving diagnosis rates, and promoting therapeutic adoption. Similarly, strategic activities by key pharmaceutical players like Gilead Sciences, Inc. and GSK plc support market expansion through advanced R&D and novel treatment development.

Market Restraints

A significant challenge is the emergence of drug resistance in chronic hepatitis B patients. Long-term antiviral therapy can lead to mutations in the virus, particularly with nucleoside and nucleotide analogs. Studies indicate that around 30% of patients develop lamivudine-resistant HBV strains within a year, while resistance to adefovir dipivoxil appears in 20-29% of patients after five years. This reduces treatment efficacy, potentially leading to increased viral loads and progression to severe liver disease, thereby restraining market growth.

Market Opportunities

Emerging pipeline products and combination therapies offer significant opportunities. Companies are developing novel therapeutics targeting viral cccDNA and integrating combination treatments to overcome resistance and achieve better viral suppression. For example, Zhimeng Biopharma initiated a Phase IIa clinical trial in August 2022 for ZM-H1505R in combination with Entecavir, demonstrating the growing focus on innovative therapies.

Market Challenges

High treatment costs for diagnosis, long-term therapy, and management of hepatitis B remain a major barrier, particularly in low- and middle-income countries. Daily oral regimens and long-term adherence requirements also pose challenges, impacting patient compliance and contributing to the development of resistance.

Market Trends

A notable trend is the emergence of next-generation therapies targeting HBV cccDNA, offering potential curative options. For instance, Precision BioSciences, Inc. reported interim results from its ELIMINATE-B trial, evaluating PBGENE-HBV, a gene-editing therapy aimed at eradicating cccDNA in HBeAg-negative chronic HBV patients, signaling a shift toward curative treatments.

Segmentation Analysis

By drug class, nucleoside analogues dominated in 2024 due to widespread prescriptions and high efficacy, with entecavir tablets prescribed in 73% of cases in Saudi Arabia and UAE. Nucleotide analogues and interferons also contribute significantly, while novel therapies are expected to boost growth.

By age group, adults dominate the market due to higher transmission rates, especially through sexual contact. Pediatric therapeutics are expanding gradually due to vaccination programs and supplemental indications.

By route of administration, oral therapeutics led the market in 2024, favored for convenience and patient compliance, while parenteral forms are gaining traction due to better bioavailability and efficacy.

Regional Outlook

North America led in 2024 with USD 1.25 billion, driven by high prevalence, advanced treatment access, and public health programs. The U.S. accounts for the largest share, supported by reimbursement policies and strong R&D. Asia Pacific is the fastest-growing region, propelled by affordable generic drugs, increasing prevalence, and government campaigns. Europe is growing steadily, and Latin America and the Middle East & Africa are emerging markets with expanding awareness and access initiatives.

Competitive Landscape

Key players include Gilead Sciences, Inc., Bristol-Myers Squibb Company, GSK plc, Excision BioTherapeutics, Arbutus Biopharma, Assembly Biosciences, and Aligos Therapeutics. Companies are focusing on R&D, strategic collaborations, and novel drug development to expand market share.

Conclusion

With a market size of USD 2.33 billion in 2024, projected to grow to USD 2.48 billion in 2025 and USD 6.25 billion by 2032, the hepatitis B therapeutics market is poised for strong growth. Rising prevalence, emergence of next-generation therapies, government initiatives, and strategic efforts by pharmaceutical companies are driving the adoption of advanced treatments globally.

Segmentation By Drug Class

• Nucleoside Analogues
• Nucleotide Analogues
• Interferons
• Others

By Age Group

• Adults
• Pediatric

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Hepatitis B, By Key Countries, 2024
• 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Advancements in Hepatitis B Treatment
• 4.5. Overview: Vaccination Coverage for Hepatitis B, Key Countries
• 4.6. Impact of Tariffs on the Market

5. Global Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Nucleoside Analogues
  • 5.1.2. Nucleotide Analogues
  • 5.1.3. Interferons
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Age Group
  • 5.2.1. Adolts
  • 5.2.2. Pediatric
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Nucleoside Analogues
  • 6.1.2. Nucleotide Analogues
  • 6.1.3. Interferons
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Age Group
  • 6.2.1. Adolts
  • 6.2.2. Pediatric
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Nucleoside Analogues
  • 7.1.2. Nucleotide Analogues
  • 7.1.3. Interferons
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Age Group
  • 7.2.1. Adolts
  • 7.2.2. Pediatric
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Nucleoside Analogues
  • 8.1.2. Nucleotide Analogues
  • 8.1.3. Interferons
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Age Group
  • 8.2.1. Adolts
  • 8.2.2. Pediatric
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Nucleoside Analogues
  • 9.1.2. Nucleotide Analogues
  • 9.1.3. Interferons
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Age Group
  • 9.2.1. Adolts
  • 9.2.2. Pediatric
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Nucleoside Analogues
  • 10.1.2. Nucleotide Analogues
  • 10.1.3. Interferons
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Age Group
  • 10.2.1. Adolts
  • 10.2.2. Pediatric
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Gilead Sciences, Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Bristol-Myers Squibb Company
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. GSK plc
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Excision BioTherapeutics, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Arbutus Biopharma
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Assembly Biosciences, Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Aligos Therapeutics
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Barinthus Biotherapeutics
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)